Egypt: Minapharm Pharmaceuticals turns to loss in 2023

Consolidated sales rose to EGP 3.892 billion last year, from EGP 3.620 billion in 2022

Staff Writer, Arab Finance

April 5, 2024

PHOTO

Minapharm Pharmaceuticals (Minapharm) posted a consolidated loss after tax and minority interest of EGP 31.98 million in 2023, versus a profit of EGP 612.66 million in 2022, as per the financial statement sent to the Egyptian Exchange (EGX).

Consolidated sales rose to EGP 3.892 billion last year, from EGP 3.620 billion in 2022.

Minapharm announced before that it posted a 24.9% YoY drop in standalone profit after tax last year, logging EGP 206.505 million, compared to EGP 274.913 million.

Minapharm Pharmaceuticals is an Egypt-based company engaged in the production and distribution of pharmaceutical products. It distributes its products within and outside Egypt.

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.